Table 3 Relative risks associated with recurrence score among ER-positive patients, stratified by treatment with tamoxifen
Score | Cases | Controls | RR1 | (95% CI) | P value | ||
|---|---|---|---|---|---|---|---|
Tamoxifen treated (55 cases and 150 controls) | |||||||
Recurrence Score | Â | Â | Â | Â | Â | Â | Â |
   Continuous2 | 55 | (100%) | 150 | (100%) | 7.6 | (2.6–21.9) | <0.0001 |
   Pre-specified categories |  |  |  |  |  |  |  |
Low risk (<18) | 16 | (29%) | 95 | (63%) | 1.0 | reference | Â |
Intermediate risk (18–30) | 22 | (40%) | 35 | (23%) | 4.0 | (1.8–8.8) |  |
High risk (≥31) | 17 | (31%) | 20 | (13%) | 6.2 | (2.4–15.8) |  |
   Quartiles3 |  |  |  |  |  |  | 0.0004 |
1st (0–8.25) | 5 | (9%) | 38 | (25%) | 1.0 | reference |  |
2nd (8.26–14.43) | 6 | (11%) | 37 | (25%) | 1.0 | (0.3–3.7) |  |
3rd (14.44–20.95) | 15 | (27%) | 38 | (25%) | 2.9 | (1.0–8.9) |  |
4th (20.96–78.78) | 53 | (53%) | 37 | (25%) | 5.8 | (2.0–16.6) |  |
Tamoxifen untreated (110 cases and 251 controls) | |||||||
Recurrence Score | Â | Â | Â | Â | Â | Â | Â |
   Continuous2 | 110 | (100%) | 251 | (100%) | 4.1 | (2.1–8.1) | <0.0001 |
   Pre-specified categories |  |  |  |  |  |  | <0.0001 |
Low risk (<18) | 40 | (36%) | 160 | (64%) | 1.0 | reference | Â |
Intermediate risk (18–30) | 32 | (29%) | 47 | (19%) | 2.7 | (1.5–5.0) |  |
High risk (≥31) | 38 | (35%) | 44 | (18%) | 3.3 | (1.8–5.9) |  |
   Quartiles4 |  |  |  |  |  |  | <0.0001 |
1st (0–7.53) | 11 | (10%) | 63 | (25%) | 1.0 | reference |  |
2nd (7.54–14.25) | 19 | (17%) | 64 | (25%) | 1.5 | (0.7–3.4) |  |
3rd (14.26–21.86) | 23 | (28%) | 62 | (25%) | 2.1 | (0.9–4.9) |  |
4th (21.87–85.82) | 57 | (52%) | 62 | (25%) | 5.3 | (2.5-1.3) |  |